Premium
Single‐Dose Pharmacokinetics of Cetirizine in Patients With Chronic Liver Disease
Author(s) -
Horsmans Y.,
Desager J. P.,
Hulhoven R.,
Harvengt C.
Publication year - 1993
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1993.tb01924.x
Subject(s) - pharmacokinetics , medicine , cetirizine , renal function , liver disease , gastroenterology , group b , creatinine , chronic liver disease , urinary system , pharmacology , cirrhosis
The pharmacokinetics of the H 1 ‐receptor antagonist cetirizine were studied from 0 to 72 hours after a single dose of 20 mg in 5 patients with chronic hepatocellular liver disease (group A), in 5 patients with chronic cholestatic liver disease (group B), and in 16 healthy volunteers. The renal function of patients and volunteers was normal (creatinine clearance ≥ 70 mh/min). Cetirizine pharmacokinetics were similar in the two groups of patients. The elimination t1/2 was prolonged in patients (mean ± standard deviation; group A: 14.32 ± 2.30 hours; group B: 13.86 ± 3.14 hours) in comparison with the values observed in volunteers (9.42 ± 2.4 hours). A reduced apparent oral body clearance also was observed in patients (group A: .48 ± .23 mL/min/kg; group B: .41 ± .09 mL/min/kg) in comparison with volunteers (.74 ± .19 mL/min/kg). No differences were observed in the mean cumulative urinary excretion between patients (group A: 69 ± 15%; group B: 69 ± 13%) and volunteers (70.7 ± 7.8%).